Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Laura Casolari"'
Autor:
Costantino Ricci, Elisa Capizzi, Francesca Giunchi, Laura Casolari, Francesco Gelsomino, Karim Rihawi, Filippo Natali, Vanina Livi, Rocco Trisolini, Michelangelo Fiorentino, Andrea Ardizzoni
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Introduction: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assessment is mandatory for the single agent pembrolizumab treatment of patients with advanced non-small cell lung cancer (NSCLC). PD-L1 testing has been validated and is curr
Externí odkaz:
https://doaj.org/article/0e4de554e2c1485b8467227e5c5680aa
Autor:
Karim Rihawi, Francesco Gelsomino, Francesca Sperandi, Barbara Melotti, Michelangelo Fiorentino, Laura Casolari, Andrea Ardizzoni
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 11 (2017)
Immune checkpoint inhibitors (ICPIs) are considered one of the most important breakthroughs in cancer treatment of the past decade; notably, different studies of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors
Externí odkaz:
https://doaj.org/article/57544b8bd285492284c3503cd8aa0d3b
Autor:
Andrea Ardizzoni, Francesco Gelsomino, Costantino Ricci, Claudio Ceccarelli, Michelangelo Fiorentino, Laura Casolari, Elisa Capizzi, Francesca Giunchi, Stefano Zagnoni, Begoña Urrios Álvarez Gómez, Rocco Trisolini
Publikováno v:
Lung Cancer. 126:9-14
Introduction The assessment of PD-L1 expression by immunohistochemistry is mandatory for the administration as first-line therapy of the anti PD-1 check-point inhibitor Pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Curre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efd515675561397db16f91fecab5f668
https://doi.org/10.1016/j.lungcan.2018.10.017
https://doi.org/10.1016/j.lungcan.2018.10.017
Autor:
Francesco Gelsomino, Elisa Capizzi, Vanina Livi, Laura Casolari, Michelangelo Fiorentino, Filippo Natali, Karim Rihawi, Rocco Trisolini, Andrea Ardizzoni, Costantino Ricci, Francesca Giunchi
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Therapeutic Advances in Medical Oncology
Therapeutic Advances in Medical Oncology
Introduction: Programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) assessment is mandatory for the single agent pembrolizumab treatment of patients with advanced non-small cell lung cancer (NSCLC). PD-L1 testing has been validated and is curr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a151c79968aaff3aac007a2c734ad75b
http://hdl.handle.net/11585/790651
http://hdl.handle.net/11585/790651
Autor:
Francesco Gelsomino, Alessandro Leonetti, Karim Rihawi, Francesca Sperandi, Laura Casolari, Barbara Melotti, Michelangelo Fiorentino, Andrea Ardizzoni
Publikováno v:
Translational Cancer Research. 6:S1484-S1488
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::134ab83686250d020f72ac4579520330
https://doi.org/10.21037/tcr.2017.11.25
https://doi.org/10.21037/tcr.2017.11.25
Autor:
Barbara Melotti, Giuseppe Lamberti, Claudia Parisi, Laura Casolari, Andrea Ardizzoni, Francesco Gelsomino, Francesca Sperandi
Publikováno v:
Cancer treatment reviews. 79
Small cell lung cancer (SCLC) was defined as a “recalcitrant cancer” because of its dismal prognosis and lack of outcome improvements in the last 30 years. Immunotherapy with checkpoint inhibitors revolutionized treatment in many cancer types and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52c244bd74d8f227aee74ba82092c259
https://pubmed.ncbi.nlm.nih.gov/31491661
https://pubmed.ncbi.nlm.nih.gov/31491661
Autor:
Michelangelo Fiorentino, Francesca Sperandi, Laura Casolari, Francesco Gelsomino, Andrea Ardizzoni, Karim Rihawi, Barbara Melotti
Publikováno v:
Therapeutic Advances in Respiratory Disease, Vol 11 (2017)
Immune checkpoint inhibitors (ICPIs) are considered one of the most important breakthroughs in cancer treatment of the past decade; notably, different studies of programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1085dc49f636ac232b4b3df4c5a5c9f
https://pubmed.ncbi.nlm.nih.gov/28818019
https://pubmed.ncbi.nlm.nih.gov/28818019
Autor:
Elisabetta Nobili, Francesco Gelsomino, Giampaolo Tortora, Karim Rihawi, Laura Casolari, Chiara Ciccarese, Francesco Massari, Donatella Grilli
Publikováno v:
Expert review of anticancer therapy. 16(7)
Enzalutamide - a non-steroidal second-generation antiandrogen - represents an active treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) in both chemotherapy-naïve and docetaxel-pretreated settings, based on th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df6d7b2bd6b8f33c61b70b6232fcc53b
https://pubmed.ncbi.nlm.nih.gov/27210425
https://pubmed.ncbi.nlm.nih.gov/27210425
Autor:
Maria Cristiana, Franceschini, Paola, Ferro, Pier Aldo, Canessa, Enrico, Battolla, Paolo, Dessanti, Alessandro, Valentino, Laura, Casolari, Vincenzo, Fontana, Riccardo, Pezzi, Franco, Fedeli, Maria Pia, Pistillo, Silvio, Roncella
Publikováno v:
Anticancer research. 34(12)
Mesothelin (SMRP) is regarded as a biomarker of malignant pleural mesothelioma (MPM). Herein, we analyzed the contribution of SMRP detection in pleural effusion and in serum to the diagnosis of MPM with non-positive cytology.The present study include
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f4dc3c4ef820e2ae928c9b0747d8cd7
https://pubmed.ncbi.nlm.nih.gov/25503183
https://pubmed.ncbi.nlm.nih.gov/25503183
Autor:
Laura Ottaggio, Paola Monti, Prema Iyer, Paola Menichini, Debora Russo, Barry Gold, Alberto Inga, Gilberto Fronza, Laura Casolari, Ilaria Traverso
Publikováno v:
Mutation research. 683(1-2)
We recently demonstrated that Polζ and Rev1 contribute to alleviate the lethal effects of Me-lex, which selectively generates 3-methyladenine, by error prone lesion bypass. In order to determine the role of Polη in the biological fate of Me-lex ind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f71b0e5cdb2f9d52639f308468dd3b6d
https://pubmed.ncbi.nlm.nih.gov/19874831
https://pubmed.ncbi.nlm.nih.gov/19874831